EP3886909A4 - Hilfsstoffverbindungen zur proteinverarbeitung - Google Patents

Hilfsstoffverbindungen zur proteinverarbeitung Download PDF

Info

Publication number
EP3886909A4
EP3886909A4 EP19889759.7A EP19889759A EP3886909A4 EP 3886909 A4 EP3886909 A4 EP 3886909A4 EP 19889759 A EP19889759 A EP 19889759A EP 3886909 A4 EP3886909 A4 EP 3886909A4
Authority
EP
European Patent Office
Prior art keywords
excipients
compounds
protein processing
protein
processing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19889759.7A
Other languages
English (en)
French (fr)
Other versions
EP3886909A1 (de
Inventor
David S. Soane
Philip Wuthrich
Robert P. Mahoney
Mark Moody
Daniel G. GREENE
Neil Schauer
Subhashchandra NAIK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Comera Life Sciences Inc
Original Assignee
Comera Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Comera Life Sciences Inc filed Critical Comera Life Sciences Inc
Publication of EP3886909A1 publication Critical patent/EP3886909A1/de
Publication of EP3886909A4 publication Critical patent/EP3886909A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP19889759.7A 2018-11-29 2019-11-26 Hilfsstoffverbindungen zur proteinverarbeitung Withdrawn EP3886909A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773018P 2018-11-29 2018-11-29
PCT/US2019/063374 WO2020112855A1 (en) 2018-11-29 2019-11-26 Excipient compounds for protein processing

Publications (2)

Publication Number Publication Date
EP3886909A1 EP3886909A1 (de) 2021-10-06
EP3886909A4 true EP3886909A4 (de) 2023-03-29

Family

ID=70853658

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19889759.7A Withdrawn EP3886909A4 (de) 2018-11-29 2019-11-26 Hilfsstoffverbindungen zur proteinverarbeitung

Country Status (5)

Country Link
EP (1) EP3886909A4 (de)
JP (1) JP2022513142A (de)
KR (1) KR20210096633A (de)
CA (1) CA3120023A1 (de)
WO (1) WO2020112855A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
EP4337166A1 (de) * 2021-05-10 2024-03-20 Merck Patent GmbH Digitale auswahl von viskositätsreduzierenden hilfsstoffen für proteinformulierungen
CN116172945B (zh) * 2022-07-26 2025-02-14 华润三九（南昌）药业有限公司 一种对乙酰氨基酚口服溶液的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070501A1 (en) * 2015-10-23 2017-04-27 Reform Biologics, Llc Excipient compounds for biopolymer formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3128117A1 (de) * 1980-07-29 1982-03-11 Yamanouchi Pharmaceutical Co., Ltd., Tokyo Neue phenyl-aethylaminderivate, verfahren zu ihrer herstellung
TWI504597B (zh) * 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
NZ592095A (en) * 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
JP5730211B2 (ja) * 2008-11-20 2015-06-03 バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． ウイルスのアルギニン不活化
US10478498B2 (en) * 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) * 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
JP2020507593A (ja) * 2017-02-16 2020-03-12 リフォーム バイオロジクス、エルエルシー タンパク質処理用賦形剤化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070501A1 (en) * 2015-10-23 2017-04-27 Reform Biologics, Llc Excipient compounds for biopolymer formulations

Also Published As

Publication number Publication date
JP2022513142A (ja) 2022-02-07
CA3120023A1 (en) 2020-06-04
EP3886909A1 (de) 2021-10-06
KR20210096633A (ko) 2021-08-05
WO2020112855A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
EP3765960A4 (de) Ereignisstromverarbeitung
EP3852745A4 (de) Verbindungen zur behandlung bestimmter leukämien
EP3886909A4 (de) Hilfsstoffverbindungen zur proteinverarbeitung
MA55325A (fr) Composés pour le traitement de maladies pd-l1
MA52219A (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
EP3600434A4 (de) Behandlung von pulmonaler hypertonie
EP3455205A4 (de) Peptidomimetika zur behandlung einer novovirusinfektion
EP3755804A4 (de) Zusammensetzungen zur behandlung von nasser altersbedingter makuladegeneration
EP3496662A4 (de) Aus seide gewonnenes protein zur behandlung von entzündungen
EP3790867A4 (de) Kdm1a-hemmer zur behandlung von krankheiten
EP3762407A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs mit ecm-affinitätspeptiden, die an zytokine gebunden sind
EP3405183A4 (de) Adamatanderivate zur behandlung einer filovirusinfektion
EP3846821A4 (de) Kombinationstherapie zur behandlung von lebererkrankungen
EP3504204A4 (de) Indazolyl-l,2,4-thiadiazolamine und zugehörige verbindungen zur hemmung der rho-assoziierten proteinkinase und zur behandlung von krankheiten
EP3773632A4 (de) Verfahren zur behandlung von egfrviii-exprimierenden glioblastomen
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3773221A4 (de) Behandlung von hydrocephalus
EP3593803A4 (de) Verbindungen zur behandlung von durch oxalatakkumulation verursachten krankheiten
MA54522A (fr) Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire
EP3859332A4 (de) Testverfahren für glykiertes hämoglobin (% )
EP3746283A4 (de) Verarbeitung einer objektrepräsentation
EP3911313A4 (de) Thienyl-anilin-verbindungen zur behandlung von hauterkrankungen
MA51738A (fr) Composés pour le traitement de la douleur
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210628

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: COMERA LIFE SCIENCES, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/42 20060101ALI20221116BHEP

Ipc: C07K 16/32 20060101ALI20221116BHEP

Ipc: C07K 16/28 20060101ALI20221116BHEP

Ipc: C07K 16/24 20060101ALI20221116BHEP

Ipc: C07K 16/22 20060101ALI20221116BHEP

Ipc: C07K 16/06 20060101ALI20221116BHEP

Ipc: A61K 9/08 20060101ALI20221116BHEP

Ipc: A61K 9/00 20060101ALI20221116BHEP

Ipc: A61K 47/26 20060101ALI20221116BHEP

Ipc: C07K 16/00 20060101ALI20221116BHEP

Ipc: A61K 47/42 20170101ALI20221116BHEP

Ipc: A61K 47/24 20060101ALI20221116BHEP

Ipc: A61K 47/20 20060101ALI20221116BHEP

Ipc: A61K 47/18 20170101ALI20221116BHEP

Ipc: A61K 47/12 20060101ALI20221116BHEP

Ipc: A61K 39/395 20060101ALI20221116BHEP

Ipc: A61K 47/22 20060101AFI20221116BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20230223

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/42 20060101ALI20230217BHEP

Ipc: C07K 16/32 20060101ALI20230217BHEP

Ipc: C07K 16/28 20060101ALI20230217BHEP

Ipc: C07K 16/24 20060101ALI20230217BHEP

Ipc: C07K 16/22 20060101ALI20230217BHEP

Ipc: C07K 16/06 20060101ALI20230217BHEP

Ipc: A61K 9/08 20060101ALI20230217BHEP

Ipc: A61K 9/00 20060101ALI20230217BHEP

Ipc: A61K 47/26 20060101ALI20230217BHEP

Ipc: C07K 16/00 20060101ALI20230217BHEP

Ipc: A61K 47/42 20060101ALI20230217BHEP

Ipc: A61K 47/24 20060101ALI20230217BHEP

Ipc: A61K 47/20 20060101ALI20230217BHEP

Ipc: A61K 47/18 20060101ALI20230217BHEP

Ipc: A61K 47/12 20060101ALI20230217BHEP

Ipc: A61K 39/395 20060101ALI20230217BHEP

Ipc: A61K 47/22 20060101AFI20230217BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20250603